A Study to Compare the Experiences of Taking Daily Growth Hormone Injections to Weekly Ngenla in Children With Low Levels of Growth Hormone

Pediatric Growth Hormone Deficiency Clinical Trial

Official title:

A MULTICENTER LOW-INTERVENTIONAL STUDY TO EVALUATE AND MONITOR TREATMENT EXPERIENCE WITH WEEKLY GROWTH HORMONE (NGENLA) VERSUS DAILY GROWTH HORMONE INJECTIONS IN CHILDREN WITH GROWTH HORMONE DEFICIENCY

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT06113952
• Other study ID #: C0311024
• Status: Withdrawn
• Start date: January 2024
• Est. completion date: October 17, 2025

Study information

• Verified date: October 2023
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to learn about: - how children stick to taking their injections - their experience with the study medicines (Ngenla and daily growth hormone) prescribed to children with low levels of growth hormone. This study is seeking participants who: - are being treated or are ready to start treatment with daily growth hormone or Ngenla. - use a sharps bin to collect used needles. The study medicines will be given as per regular care agreed with the doctor. The study will compare participant experiences to help us see: - the difference in how the participants stick to taking their daily growth hormone injections compared to participants using once weekly Ngenla. Participants will take part in this study for up to 14 months. During this time, they will have 3 study visits at the study clinic. The participants will use the HealthBeacon™ smart sharps bin for collecting the used needles or injections.

Description:

This multicenter, international, longitudinal, prospective, site-based, low-interventional study aims to evaluate and monitor treatment experience, defined by treatment adherence and persistence, in children aged 3-16 years old with a diagnosis of pediatric growth hormone deficiency (pGHD), receiving either daily growth hormone (dGH) treatment or once weekly Ngenla. The study is planned to be conducted in a total of 50 participating sites distributed across Belgium, Canada, France, Italy, Luxembourg, Spain, UK, and US. Data on treatment adherence and persistence will be collected in real-time over a period of 12 months using the HealthBeacon™ Smart Sharps Bin™ as a treatment monitoring device. Additional data, including demographic and clinical characteristics, will be collected at three timepoints, in line with the routine care in each participating site and/or country, over a maximum period of 14 months. Approximately 400 participants will be enrolled in the study (approximately 200 participants prescribed dGH injections and approximately 200 prescribed Ngenla).

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: October 17, 2025
• Est. primary completion date: October 17, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 3 Years to 16 Years

Eligibility

Inclusion Criteria:

1. Children of any sex aged 3-16 years at baseline

2. Children that have received a diagnosis of pGHD requiring GH injections.

3. Children that are currently being treated (dGH/Ngenla) or are treatment naïve but ready to start treatment.

4. Those who currently use a sharps bin to collect used needles [as per normal standard of care (SoC)].

Exclusion Criteria:

1. Children with psychosocial dwarfism.

2. Children born small for gestational age (SGA)

3. Children with chromosomal abnormalities

4. Children with other causes of short stature, such as uncontrolled primary hypothyroidism or rickets.

5. Children with a history of cancer.

7. Children with other acute medical or psychiatric condition

Related Conditions & MeSH terms

• Dwarfism, Pituitary
• Endocrine System Diseases
• Pediatric Growth Hormone Deficiency

Intervention

Device:
• Sharps bin to collect used needles/injections
Enrolled participants will be provided with a Smart Sharps Bin. The bin will collect used needles over a period of 12 months starting from enrollment.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Pfizer

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean Adherence To Ngenla and daily growth hormone	The adherence for Ngenla and daily growth hormone followed the medication possession ratio definition(MPR). The MPR is calculated from the total number of injections used and collected in the Smart Sharps Bin™ .	12 months
Secondary	Percentage of scheduled injections taken per participant	The percentage of scheduled injections taken per participant is calculated as the proportion of actual number of injections with Ngenla or daily growth hormone used from the total number of expected injections.	12 months
Secondary	Change from baseline in Life Interference Questionnaire-Growth Hormone Deficiency I (LIQ-GHD I) questionnaire	The LIQ-GHD I instrument uses either a 5 point scale from never to always or very easy to very difficult or a 7 point scale from extremely convenient to extremely inconvenient.; It contains the following subscales: Pen ease of use; Ease of the injection schedule; Satisfaction with overall treatment experience; Willingness to continue injection schedule; Patient life interference; Number of missed injections during the past 4 weeks(two questions asking for number of missed injections and reasons); Caregiver life interference	12 months
Secondary	Change from baseline in Quality of Life in Short Stature Youth (QoLISSY) questionnaire for patients and for caregivers	The QoLISSY questionnaire is a 5 point scale from not at all/never to extremely/always.; It evaluates the following health related quality of life domains for participants and their caregivers: Physical impact of height; Social impact of height; Emotional impact of height	12 months
Secondary	Healthcare practitioner (HCP) preference survey	HCP preference and satisfaction survey for treatment regimen and treatment experience (daily or weekly injections or no preference) and satisfaction rated from very satisfied to very dissatisfied.	12 months
Secondary	Change from baseline in effectiveness evaluations for Ngenla and daily growth hormone	Height in cm, weight in kg, and BMI in kg/m2 at diagnosis and follow-up visits and annualized height velocity in cm.	12 month
Secondary	Presence or absence of factors influencing adherence	Lifestyle factors are assessed: travel, illness, overnight sleep; injection administration by caregiver/nurse or self-administration Number of concomitant medications and route of administration are collected	12 months
Secondary	Mean Adherence To Ngenla and daily growth hormone for age subgroups.	-Different age groups: 3-7 years/8-11 years/12-16 years The adherence for Ngenla and daily growth hormone follows the medication possession ratio definition(MPR). The MPR is calculated from the total number of injections used and collected in the Smart Sharps Bin™ .	12 months
Secondary	Mean Adherence To Ngenla and daily growth hormone for switch participants	- Switch participants: dGH to Ngenla and vice versa The adherence for Ngenla and daily growth hormone follows the medication possession ratio definition(MPR). The MPR is calculated from the total number of injections used and collected in the Smart Sharps Bin™ .	12 months
Secondary	Mean Adherence To Ngenla and daily growth hormone for naive/non-naive subgroups.	- Treatment naïve vs non-naïve (either dGH or Ngenla) The adherence for Ngenla and daily growth hormone follows the medication possession ratio definition(MPR). The MPR is calculated from the total number of injections used and collected in the Smart Sharps Bin™ .	12 months
Secondary	Number of participants who discontinued Ngenla or daily growth hormone	Persistency/discontinuation is evaluated at specific time windows, after patients stop utilizing the sharps bin.	12 months
Secondary	Percent of participants who discontinued Ngenla or daily growth hormone	Persistency/discontinuation is evaluated at specific time windows, after patients stop utilizing the sharps bin.	12 months
Secondary	Number of participants who switch growth hormone treatment	Number of participants who switch from daily to weekly GH injections or from weekly to daily GH injections is reported.	12 months
Secondary	Percentage of participants who switch growth hormone treatment	Percentage of participants who switch from daily to weekly GH injections or from weekly to daily GH injections is reported.	12 months

External Links

•   To obtain contact information for a study center near you, click here.